Inclusion Criteria:  Female participants (age between 40 and 75 years old) who are postmenopausal or had post-bilateral surgical oophorectomy not linked to a history of cancer.  Participants who are overtly healthy. Body weight within 40.0 and 95.0 kg and body mass index (BMI) within the range 18.0 and 30 kg/m2 (inclusive).  Capable of giving signed informed consent.  Exclusion Criteria:  Subject has clinical signs and symptoms consistent with COVID-19, e.g., fever, dry cough, dyspnea, loss of taste and smell, sore throat, fatigue or confirmed infection by appropriate laboratory test within the last 4 weeks prior to Screening.  Subject who had severe course of COVID-19 (i.e., hospitalization, extracorporeal membrane oxygenation, mechanically ventilated).  Frequent headaches and/or migraine, recurrent nausea and/or vomiting (for vomiting only: more than twice a month).  Blood donation, any volume (usually approximately 500 mL), within 2 months before inclusion.  Presence or history of drug hypersensitivity, or allergic disease diagnosed and treated by a physician.  History or presence of drug or alcohol abuse (alcohol consumption more than 40 g per day).  Smoking regularly more than 5 cigarettes or equivalent per week, unable to stop smoking during the study (occasional smoker can be enrolled).  Excessive consumption of beverages containing xanthine bases (more than 5 cups or glasses per day).  Subjects who are occupationally exposed to radiation as defined in the Ionizing Radiation Regulations 2017.  Participation in a trial with [13C] or [14C] radiolabeled medication in the 12 months preceding the study.  The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.